Transcriptional and metabolic effects of aspartate-glutamate carrier isoform 1 (AGC1) downregulation in mouse oligodendrocyte precursor cells (OPCs)
© 2024. The Author(s)..
Aspartate-glutamate carrier isoform 1 (AGC1) is a carrier responsible for the export of mitochondrial aspartate in exchange for cytosolic glutamate and is part of the malate-aspartate shuttle, essential for the balance of reducing equivalents in the cells. In the brain, mutations in SLC25A12 gene, encoding for AGC1, cause an ultra-rare genetic disease, reported as a neurodevelopmental encephalopathy, whose symptoms include global hypomyelination, arrested psychomotor development, hypotonia and seizures. Among the biological components most affected by AGC1 deficiency are oligodendrocytes, glial cells responsible for myelination processes, and their precursors [oligodendrocyte progenitor cells (OPCs)]. The AGC1 silencing in an in vitro model of OPCs was documented to cause defects of proliferation and differentiation, mediated by alterations of histone acetylation/deacetylation. Disrupting AGC1 activity could possibly reduce the availability of acetyl groups, leading to perturbation of many biological pathways, such as histone modifications and fatty acids formation for myelin production. Here, we explore the transcriptome of mouse OPCs partially silenced for AGC1, reporting results of canonical analyses (differential expression) and pathway enrichment analyses, which highlight a disruption in fatty acids synthesis from both a regulatory and enzymatic stand. We further investigate the cellular effects of AGC1 deficiency through the identification of most affected transcriptional networks and altered alternative splicing. Transcriptional data were integrated with differential metabolite abundance analysis, showing downregulation of several amino acids, including glutamine and aspartate. Taken together, our results provide a molecular foundation for the effects of AGC1 deficiency in OPCs, highlighting the molecular mechanisms affected and providing a list of actionable targets to mitigate the effects of this pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cellular & molecular biology letters - 29(2024), 1 vom: 29. März, Seite 44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Balboni, Nicola [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s11658-024-00563-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370432126 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370432126 | ||
| 003 | DE-627 | ||
| 005 | 20240401233118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s11658-024-00563-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM370432126 | ||
| 035 | |a (NLM)38553684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balboni, Nicola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcriptional and metabolic effects of aspartate-glutamate carrier isoform 1 (AGC1) downregulation in mouse oligodendrocyte precursor cells (OPCs) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Aspartate-glutamate carrier isoform 1 (AGC1) is a carrier responsible for the export of mitochondrial aspartate in exchange for cytosolic glutamate and is part of the malate-aspartate shuttle, essential for the balance of reducing equivalents in the cells. In the brain, mutations in SLC25A12 gene, encoding for AGC1, cause an ultra-rare genetic disease, reported as a neurodevelopmental encephalopathy, whose symptoms include global hypomyelination, arrested psychomotor development, hypotonia and seizures. Among the biological components most affected by AGC1 deficiency are oligodendrocytes, glial cells responsible for myelination processes, and their precursors [oligodendrocyte progenitor cells (OPCs)]. The AGC1 silencing in an in vitro model of OPCs was documented to cause defects of proliferation and differentiation, mediated by alterations of histone acetylation/deacetylation. Disrupting AGC1 activity could possibly reduce the availability of acetyl groups, leading to perturbation of many biological pathways, such as histone modifications and fatty acids formation for myelin production. Here, we explore the transcriptome of mouse OPCs partially silenced for AGC1, reporting results of canonical analyses (differential expression) and pathway enrichment analyses, which highlight a disruption in fatty acids synthesis from both a regulatory and enzymatic stand. We further investigate the cellular effects of AGC1 deficiency through the identification of most affected transcriptional networks and altered alternative splicing. Transcriptional data were integrated with differential metabolite abundance analysis, showing downregulation of several amino acids, including glutamine and aspartate. Taken together, our results provide a molecular foundation for the effects of AGC1 deficiency in OPCs, highlighting the molecular mechanisms affected and providing a list of actionable targets to mitigate the effects of this pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mitochondria | |
| 650 | 4 | |a Neurodevelopment | |
| 650 | 4 | |a Oligodendrocytes | |
| 650 | 4 | |a Omics analysis | |
| 650 | 4 | |a SLC25A12/aralar1/AGC1 deficiency | |
| 650 | 4 | |a White matter disorder | |
| 650 | 7 | |a aspartate-glutamate carrier |2 NLM | |
| 650 | 7 | |a Aspartic Acid |2 NLM | |
| 650 | 7 | |a 30KYC7MIAI |2 NLM | |
| 650 | 7 | |a Protein Isoforms |2 NLM | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a Amino Acid Transport Systems, Acidic |2 NLM | |
| 650 | 7 | |a Antiporters |2 NLM | |
| 700 | 1 | |a Babini, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Poeta, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Protti, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Mercolini, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Magnifico, Maria Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Barile, Simona Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Massenzio, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pignataro, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgi, Federico M |e verfasserin |4 aut | |
| 700 | 1 | |a Lasorsa, Francesco Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Barbara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular & molecular biology letters |d 1998 |g 29(2024), 1 vom: 29. März, Seite 44 |w (DE-627)NLM095479252 |x 1689-1392 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:29 |g month:03 |g pages:44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s11658-024-00563-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 29 |c 03 |h 44 | ||